Items Tagged ‘myeloproliferative neoplasm’

December 6th, 2017

Fedratinib May Represent New Option for Jakafi-Resistant Myelofibrosis


Patients with myelofibrosis resistant or intolerant to Jakafi (ruxolitinib) may have an alternative treatment option with a novel JAK2-selective inhibitor fedratinib, according to the results of clinical study recently published in the medical journal Lancet.1 About Myelofibrosis Myelofibrosis is a type of blood cancer known as a myeloproliferative neoplasm that is chronic and progressive in […]

View full entry

Tags: essential thrombocytosis, fedratinib, jakafi, mpn, myelofibrosis, myeloproliferative neoplasm, Myeloproliferative Neoplasms MPN, News, polycythemia vera, ruxolitinib

December 20th, 2016

5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis


An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term survival, compared to other treatment options for patients with myelofibrosis. Perhaps even more importantly, the data suggests that treatment with Jakafi should be used much earlier in the course of a patient’s disease because it […]

View full entry

Tags: 2016, Acute Myeloid Leukemia, American Society of Hematology, ASH, COMFORT-I, COMFORT-II, essential thrombocythemia, jakafi, MF, mpn, myelofibrosis, myeloproliferative neoplasm

April 27th, 2016

Pacritinib Development in Myelofibrosis Placed on Clinical Hold by the FDA


The investigative agent, pacritinib, being evaluated for treatment of myelofibrosis has been placed on full clinical hold by the United States Food and Drug Administration (FDA). All trials including treatment involving pacritinib have been stopped, and the New Drug Application (NDA) to the FDA for pacritinib has been withdrawn.1 Myelofibrosis is a type of blood […]

View full entry

Tags: clinical hold, fda, mpn, myelofibrosis, myeloproliferative neoplasm, Myeloproliferative Neoplasms MPN, NDA, News, pacritinib, withdrawn